DRUG
Mazdutide
Administered SC
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
Status
Completed
Phase
Phase 2
Enrollment
308
Locations
25
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Interventions
Treatment arms and agents.
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
Feb 10, 2025
Study start
Feb 6, 2025
Primary completion
Mar 19, 2026
Study completion
May 19, 2026
Results posted
Not reported
Registry updated
Jul 16, 2026
Outcomes
What the study measures.
Primary outcomes
Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method
Time frame · Baseline, Week 28
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 21 Years
- Maximum age
- 65 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Current AUD diagnosis as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria. Exclusion Criteria: * Have a history of significant active or unstable major depressive disorder, suicidal ideation, or other severe psychiatric disorder within the last 12 months. * Have initiated psychotherapy, changed the intensity of psychotherapy, or other nondrug therapies (for example, acupuncture or hypnosis) within 8 weeks prior to enrollment. * Have received any medication for AUD in the last 30 days including but not limited to, disulfiram, acamprosate, naltrexone, gabapentin, baclofen, or topiramate. * Other protocol-specific inclusion and exclusion criteria may apply.
Study locations
25 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
Woodland Resarch Northwest/ERG
Rogers, Arkansas, United States
Ark Clinical Research - Fountain Valley
Fountain Valley, California, United States
Synergy San Diego
Lemon Grove, California, United States
Headlands Research-Artemis San Diego
San Diego, California, United States
Research Centers of America ( Hollywood )
Hollywood, Florida, United States
K2 Medical Research - Maitland
Maitland, Florida, United States
K2 Medical Research
Maitland, Florida, United States
Clinical Neuroscience Solutions Inc
Orlando, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
K2 Medical Research - Tampa
Tampa, Florida, United States
CenExel iResearch, LLC (CenExel iRA)
Decatur, Georgia, United States
DelRicht Research
Mandeville, Louisiana, United States
Adams Clinical
Watertown, Massachusetts, United States
Vitalix Clinical
Worcester, Massachusetts, United States
Redbird Research LLC
Las Vegas, Nevada, United States
Richmond Behavioral Associates
Staten Island, New York, United States
Ichor Research
Syracuse, New York, United States
Davis Clinical
The Bronx, New York, United States
Summit Headlands
Portland, Oregon, United States
Rhode Island Mood & Memory Research Institute
East Providence, Rhode Island, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Clinical Neuroscience Solutions Inc
Memphis, Tennessee, United States
FutureSearch Trials of Dallas
Dallas, Texas, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Mazdutide.
NCT IDStudyPhase / statusEnrollmentUpdated
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
West China Hospital · Metabolic Dysfunction-Associated Steatohepatitis · Hepatic Steatosis
Phase 2 / Phase 3
Not yet recruiting
60
2026-07
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Tianjin Medical University · Type 2 Diabetes Mellitus (T2DM) · Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus
Not applicable
Not yet recruiting
72
2026-07
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
China National Center for Cardiovascular Diseases · Obesity & Overweight · Coronary Heart Disease
Phase 4
Not yet recruiting
116
2026-06
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)
Shandong Provincial Hospital · Prediabetes · Impaired Fasting Glucose
Phase 4
Not yet recruiting
150
2026-06
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Type 2 Diabetes · Obesity
Phase 3
Completed
349
2026-06
GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
China-Japan Friendship Hospital · Obesity
Not applicable
Recruiting
200
2026-06
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Innovent Biologics (Suzhou) Co. Ltd. · Overweight · Obesity
Phase 3
Recruiting
336
2026-05
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.